|
|
胰腺神经内分泌肿瘤的流行病学、诊断学及药物治疗研究进展
|
Abstract:
胰腺神经内分泌肿瘤是来源于弥散的胰腺神经内分泌细胞，被认为是一种罕见的胰腺肿瘤。随着医学影像学、基因组学、免疫组织病理学等相关学科的发展，胰腺神经内分泌肿瘤的正确诊断率及检出率越来越高。胰腺神经内分泌肿瘤被正确地诊断及病理学分级对患者后续治疗选择是至关重要的。此外，胰腺神经内分泌肿瘤的治疗与肿瘤分期、肿瘤分级分化、激素产生、肿瘤负荷和肿瘤进展高度相关。随着分子靶向药物和生长抑素类似物的问世，胰腺神经内分泌肿瘤的药物治疗取得了很大进展。目前，全身治疗药物方案包括生长抑素类似物(SSAs)、分子靶向药物、细胞毒性化疗药物、免疫检查点抑制剂和肽受体放射性核素治疗(PRRT)。已被临床使用和正在进行临床试验的药物都显著提高了胰腺神经内分泌肿瘤患者的生存率。本文就胰腺神经内分泌肿瘤的流行病学、诊断学及药物治疗的最新进展做一综述。
Pancreatic neuroendocrine neoplasm is derived from diffused pancreatic neuroendocrine cells and is considered to be a rare pancreatic tumor. With the development of medical imaging, genomics, immunohistopathology and other related disciplines, the correct diagnosis rate and detection rate of pancreatic neuroendocrine neoplasm are getting higher and higher. The correct diagnosis and pathological grading of pancreatic neuroendocrine neoplasm are very important for the choice of subsequent treatment. In addition, the treatment of pancreatic neuroendocrine neoplasm is highly correlated with tumor stage, tumor grade and differentiation, hormone production, tumor burden and tumor progression. With the advent of molecular targeted drugs and somatostatin analogues, great progress has been made in the drug therapy of pancreatic neuroendocrine neoplasm. At pre-sent, systemic therapeutic drug regimens include somatostatin analogues (SSAs), molecular tar-geted drugs, cytotoxic chemotherapeutic drugs, immune checkpoint inhibitors and peptide recep-tor radionuclide therapy (PRRT). Drugs in clinical use and ongoing clinical trials have significantly improved survival in patients with pancreatic neuroendocrine neoplasm. This article reviews the latest advances in epidemiology, diagnostics and drug treatment of pancreatic neuroendocrine ne-oplasm.
| [1] | Nagtegaal, I.D., Odze, R.D., Klimstra, D., et al. (2020) The 2019 WHO Classification of Tumours of the Digestive Sys-tem. Histopathology, 76, 182-188. https://doi.org/10.1111/his.13975 |
| [2] | Pavel, M., Oberg, K., Falconi, M., et al. (2020) Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 31, 844-860.
https://doi.org/10.1016/j.annonc.2020.03.304 |
| [3] | Dasari, A., Shen, C., Halperin, D., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA On-cology, 3, 1335-1342.
https://doi.org/10.1001/jamaoncol.2017.0589 |
| [4] | Cives, M. and Strosberg, J.R. (2018) Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians, 68, 471-487. https://doi.org/10.3322/caac.21493 |
| [5] | Shah, M.H., Goldner, W.S., Benson, A.B., et al. (2021) Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Com-prehensive Cancer Network, 19, 839-868.
https://doi.org/10.6004/jnccn.2021.0032 |
| [6] | Sunami, K., Ichikawa, H., Kubo, T., et al. (2019) Feasibility and Util-ity of a Panel Testing for 114 Cancer-Associated Genes in a Clinical Setting: A Hospital-Based Study. Cancer Science, 110, 1480-1490.
https://doi.org/10.1111/cas.13969 |
| [7] | Stang, A., Wellmann, I., Holleczek, B., et al. (2022) Incidence and Relative Survival of Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Neoplasms in Germany, 2009-2018. An In-Depth Analysis of Two Population-Based Cancer Registries. Cancer Epidemiology, 79, Article ID: 102204. https://doi.org/10.1016/j.canep.2022.102204 |
| [8] | Chang, J.S., Chen, L.T., Shan, Y.S., et al. (2021) An Updated Analysis of the Epidemiologic Trends of Neuroendocrine Tumors in Taiwan. Scientific Reports, 11, Article No. 7881. https://doi.org/10.1038/s41598-021-86839-2 |
| [9] | Koizumi, T., Otsuki, K., Tanaka, Y., et al. (2022) Epidemiology of Neuroendocrine Neoplasmas in Japan: Based on Analysis of Hospital-Based Cancer Registry Data, 2009-2015. BMC Endocrine Disorders, 22, Article No. 105.
https://doi.org/10.1186/s12902-022-01016-4 |
| [10] | Fu, M., Yu, L., Yang, L., et al. (2022) Gender Differences in Pancreatic Neuroendocrine Neoplasms: A Retrospective Study Based on the Population of Hubei Province, China. Fron-tiers in Endocrinology (Lausanne), 13, Article ID: 885895. https://doi.org/10.3389/fendo.2022.885895 |
| [11] | 李浩明, 曲玉清, 王先令, 等. 286例功能性胰腺神经内分泌肿瘤的临床特点及治疗: 一项单中心回顾性研究[J]. 国际内分泌代谢杂志, 2021, 41(3): 178-183. |
| [12] | Fraenkel, M., Faggiano, A. and Valk, G.D. (2015) Epidemiology of Neuroendocrine Tumors. Frontiers of Hormone Research, 44, 1-23. https://doi.org/10.1159/000381970 |
| [13] | Janson, E.T., Knigge, U., Dam, G., et al. (2021) Nordic Guidelines 2021 for Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms. Acta Oncologica, 60, 931-941.
https://doi.org/10.1080/0284186X.2021.1921262 |
| [14] | Mafficini, A. and Scarpa, A. (2019) Genetics and Epigenet-ics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrine Reviews, 40, 506-536. https://doi.org/10.1210/er.2018-00160 |
| [15] | Venizelos, A., Elvebakken, H., Perren, A., et al. (2021) The Molecular Characteristics of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrine-Related Cancer, 29, 1-14. https://doi.org/10.1530/ERC-21-0152 |
| [16] | Obazee, O., Capurso, G., Tavano, F., et al. (2018) Common Genetic Variants Associated with Pancreatic Adenocarcinoma May Also Modify Risk of Pancreatic Neuroendocrine Neoplasms. Carcinogenesis, 39, 360-367.
https://doi.org/10.1093/carcin/bgx150 |
| [17] | Pulvirenti, A., Rao, D., Mcintyre, C.A., et al. (2019) Limited Role of Chromogranin A as Clinical Biomarker for Pancreatic Neuroendocrine Tumors. HPB (Oxford), 21, 612-618. https://doi.org/10.1016/j.hpb.2018.09.016 |
| [18] | Di Giacinto, P., Rota, F., Rizza, L., et al. (2018) Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. International Journal of Endocrinology, 2018, Article ID: 8126087.
https://doi.org/10.1155/2018/8126087 |
| [19] | Lyubimova, N.V., Timofeev, Y.S., Markovich, A.A., et al. (2022) Chromogranin B in Blood Serum of Patients with Neuroendocrine Tumors. Kliniceskaja Laboratornaja Diagnostika, 67, 440-443.
https://doi.org/10.51620/0869-2084-2022-67-8-440-443 |
| [20] | Takase, Y., Naito, Y., Okabe, Y., et al. (2019) Insu-linoma-Associated Protein 1 Expression in Pancreatic Neuroendocrine Tumours in Endoscopic Ultrasound-Guided Fi-ne-Needle Aspiration Cytology: An Analysis of 14 Patients. Cytopathology, 30, 194-200. https://doi.org/10.1111/cyt.12640 |
| [21] | Baykara, Y., Xiao, Y., Yang, D.F., et al. (2022) Utility of Secretagogin as a Marker for the Diagnosis of Lung Neuroendocrine Carcinoma. Virchows Archiv, 481, 31-39. https://doi.org/10.1007/s00428-022-03312-9 |
| [22] | Wu, X.Y., Hu, Y.B., Li, H.J., et al. (2018) Diagnostic and Therapeutic Value of Progastrin-Releasing Peptide on Small-Cell Lung Cancer: A Single-Center Experience in China. Journal of Cellular and Molecular Medicine, 22, 4328-4334. https://doi.org/10.1111/jcmm.13722 |
| [23] | Korse, C.M., Taal, B.G., Vincent, A., et al. (2012) Choice of Tumour Markers in Patients with Neuroendocrine Tumours Is Dependent on the Histological Grade. A Marker Study of Chromogranin A, Neuron Specific Enolase, Progastrin-Releasing Peptide and Cytokeratin Fragments. European Journal of Cancer, 48, 662-671.
https://doi.org/10.1016/j.ejca.2011.08.012 |
| [24] | Hofland, J., Zandee, W.T. and De Herder, W.W. (2018) Role of Biomarker Tests for Diagnosis of Neuroendocrine Tumours. Nature Reviews Endocrinology, 14, 656-669. https://doi.org/10.1038/s41574-018-0082-5 |
| [25] | Nobels, F.R., Kwekkeboom, D.J., Coopmans, W., et al. (1997) Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the Alpha-Subunit of Glycoprotein Hormones. The Journal of Clinical Endocrinology & Metabolism, 82, 2622-2628. https://doi.org/10.1210/jc.82.8.2622 |
| [26] | Wang, X.L., Wang, L.X., Ding, B.Q., et al. (2022) Expression and Clinicopathological Significance of SOX11 in Small-Cell Lung Cancer. BioMed Research International, 2022, Article ID: 1707914.
https://doi.org/10.1155/2022/1707914 |
| [27] | Modlin, I.M., Drozdov, I. and Kidd, M. (2013) The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood. PLOS ONE, 8, e63364. https://doi.org/10.1371/journal.pone.0063364 |
| [28] | Kidd, M., Drozdov, I. and Modlin, I. (2015) Blood and Tissue Neuroendocrine Tumor Gene Cluster Analysis Correlate, Define Hallmarks and Predict Disease Status. Endo-crine-Related Cancer, 22, 561-575.
https://doi.org/10.1530/ERC-15-0092 |
| [29] | Pavel, M., Jann, H., Prasad, V., et al. (2017) NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. Neuroendocrinology, 104, 170-182.
https://doi.org/10.1159/000446025 |
| [30] | Modlin, I.M., Kidd, M., Falconi, M., et al. (2021) A Multigenomic Liquid Biopsy Biomarker for Neuroendocrine Tumor Disease Outperforms CgA and Has Surgical and Clinical Utility. Annals of Oncology, 32, 1425-1433.
https://doi.org/10.1016/j.annonc.2021.08.1746 |
| [31] | Modlin, I.M., Kidd, M., Oberg, K., et al. (2021) Early Identifi-cation of Residual Disease after Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signa-ture (NETest). Annals of Surgical Oncology, 28, 7506-7517.
https://doi.org/10.1245/s10434-021-10021-1 |
| [32] | Van Treijen, M.J.C., Korse, C.M., Van Leeuwaarde, R.S., et al. (2018) Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Valida-tion Study. Frontiers in Endocrinology (Lausanne), 9, Article 740. https://doi.org/10.3389/fendo.2018.00740 |
| [33] | Rossi, R.E., Elvevi, A., Gallo, C., et al. (2022) Endoscopic Tech-niques for Diagnosis and Treatment of Gastro-Entero- Pancreatic Neuroendocrine Neoplasms: Where We Are. World Journal of Gastroenterology, 28, 3258-3273.
https://doi.org/10.3748/wjg.v28.i26.3258 |
| [34] | Di Leo, M., Poliani, L., Rahal, D., et al. (2019) Pancreatic Neuro-endocrine Tumours: The Role of Endoscopic Ultrasound Biopsy in Diagnosis and Grading Based on the WHO 2017 Classification. Digestive Diseases, 37, 325-333.
https://doi.org/10.1159/000499172 |
| [35] | Crino, S.F., Ammendola, S., Meneghetti, A., et al. (2021) Comparison between EUS-Guided Fine-Needle Aspiration Cytology and EUS-Guided Fine-Needle Biopsy Histology for the Evalua-tion of Pancreatic Neuroendocrine Tumors. Pancreatology, 21, 443-450. https://doi.org/10.1016/j.pan.2020.12.015 |
| [36] | Appelstrand, A., Bergstedt, F., Elf, A.-K., et al. (2022) Endoscopic Ultrasound-Guided Side-Fenestrated Needle Biopsy Sampling Is Sensitive for Pancreatic Neuroendocrine Tumors but Inadequate for Tumor Grading: A Prospective Study. Scientific Reports, 12, Article No. 5971. https://doi.org/10.1038/s41598-022-09923-1 |
| [37] | Kos-Kud？a, B., Foltyn, W., Malczewska, A., et al. (2022) Update of the Diagnostic and Therapeutic Guidelines for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (Recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zaleceń ogólnych dotycz？cych post？powania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych uk？adu pokarmowego (rekomendowane przez Polsk？ Sie？ Guzów Neuroendokrynnych)]. Endokrynologia Polska, 73, 387-454. https://doi.org/10.5603/EP.a2022.0049 |
| [38] | Malla, S., Kumar, P. and Madhusudhan, K.S. (2021) Radiology of the Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Comprehensive Review. Abdominal Radiology (NY), 46, 919-935.
https://doi.org/10.1007/s00261-020-02773-3 |
| [39] | Luo, Y., Chen, X., Chen, J., et al. (2020) Preoperative Prediction of Pancreatic Neuroendocrine Neoplasms Grading Based on Enhanced Computed Tomography Imaging: Validation of Deep Learning with a Convolutional Neural Network. Neuroendocrinology, 110, 338-350. https://doi.org/10.1159/000503291 |
| [40] | Jawlakh, H., Velikyan, I., Welin, S., et al. (2021) 68Ga-DOTATOC-PET/MRI and 11C-5-HTP-PET/MRI Are Superior to 68Ga-DOTATOC-PET/CT for Neuroendocrine Tumour Imaging. Journal of Neuroendocrinology, 33, e12981.
https://doi.org/10.1111/jne.12981 |
| [41] | 王佩佩, 霍力, 刘宇, 等. 无功能胰腺神经内分泌肿瘤18F-FDG PET/CT显像的临床应用价值[J]. 中华核医学与分子影像杂志, 2022, 42(3): 139-143. |
| [42] | Dietrich, C.F. and Jenssen, C. (2020) Modern Ultrasound Imaging of Pancreatic Tumors. Ultrasonography, 39, 105-113. https://doi.org/10.14366/usg.19039 |
| [43] | Choi, S.J., Choi, S.H., Lee, D.Y., et al. (2022) Diagnostic Value of [68Ga]Ga-DOTA-Labeled-Somatostatin Analogue PET/MRI for Detecting Liver Metastasis in Patients with Neuroendo-crine Tumors: A Systematic Review and Meta-Analysis. European Radiology, 32, 4628-4637. https://doi.org/10.1007/s00330-021-08527-z |
| [44] | Halfdanarson, T.R., Strosberg, J.R., Tang, L., et al. (2020) The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas, 49, 863-881. https://doi.org/10.1097/MPA.0000000000001597 |
| [45] | Zhao, J., Zhao, H. and Chi, Y. (2018) Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. Neuroendocrinology, 106, 318-323. https://doi.org/10.1159/000480402 |
| [46] | Bongiovanni, A., Liverani, C., Foca, F., et al. (2021) Te-mozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A “Re-al-World” Data Analysis. Neuroendocrinology, 111, 895-906.
https://doi.org/10.1159/000513218 |
| [47] | Chatzellis, E., Angelousi, A., Daskalakis, K., et al. (2019) Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendo-crine Neoplasms. Neuroendocrinology, 109, 333-345. https://doi.org/10.1159/000500135 |
| [48] | Bardasi, C., Spallanzani, A., Benatti, S., et al. (2021) Irinotecan-Based Chemotherapy in Extrapulmonary Neuroendocrine Carcinomas: Survival and Safety Data from a Multicentric Italian Experience. Endocrine, 74, 707-713.
https://doi.org/10.1007/s12020-021-02813-y |
| [49] | Stueven, A.K., Kayser, A., Wetz, C., et al. (2019) Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. International Journal of Molecular Sciences, 20, Article 3049.
https://doi.org/10.3390/ijms20123049 |
| [50] | Carmona-Bayonas, A., Jiménez-Fonseca, P., Custodio, A., et al. (2017) Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tu-mors. Current Oncology Reports, 19, Article No. 72. https://doi.org/10.1007/s11912-017-0633-2 |
| [51] | Merola, E., Alonso Gordoa, T., Zhang, P., et al. (2021) Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%? Oncologist, 26, 294-301. https://doi.org/10.1002/onco.13633 |
| [52] | Pavel, M., O’Toole, D., Costa, F., et al. (2016) ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of In-testinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocri-nology, 103, 172-185. https://doi.org/10.1159/000443167 |
| [53] | 吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020) [J]. 中华外科杂志, 2021, 59(6): 401-421. |
| [54] | Yao, J.C., Shah, M.H., Ito, T., et al. (2011) Everolimus for Advanced Pancreatic Neuroendocrine Tumors. The New England Journal of Medicine, 364, 514-523. https://doi.org/10.1056/NEJMoa1009290 |
| [55] | Baudin, E., Berruti, A., Giuliano, M., et al. (2021) First Long-Term Results on Efficacy and Safety of Long-Acting Pasireotide in Combination with Everolimus in Patients with Advanced Carcinoids (NET) of the Lung/Thymus: Phase II LUNA Trial. JCO, 39, 8574. https://doi.org/10.1200/JCO.2021.39.15_suppl.8574 |
| [56] | Hijioka, S., Morizane, C., Ikeda, M., et al. (2021) Cur-rent Status of Medical Treatment for Gastroenteropancreatic Neuroendocrine Neoplasms and Future Perspectives. Japa-nese Journal of Clinical Oncology, 51, 1185-1196.
https://doi.org/10.1093/jjco/hyab076 |
| [57] | Dromain, C., Loaiza-Bonilla, A., Mirakhur, B., et al. (2021) Novel Tu-mor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors. Oncologist, 26, E632-E638. https://doi.org/10.1002/onco.13669 |
| [58] | Chang, S.-C., Tsai, C.-Y., Liu, K.-H., et al. (2021) Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor with Liver Metastases: A Case Report and Literature Review. Frontiers in Endocrinology (Lausanne), 12, Article 639967. https://doi.org/10.3389/fendo.2021.639967 |
| [59] | Couvelard, A., O’Toole, D., Turley, H., et al. (2005) Microvascu-lar Density and Hypoxia-Inducible Factor Pathway in Pancreatic Endocrine Tumours: Negative Correlation of Microvas-cular Density and VEGF Expression with Tumour Progression. British Journal of Cancer, 92, 94-101. https://doi.org/10.1038/sj.bjc.6602245 |
| [60] | Xu, J., Shen, L., Bai, C., et al. (2020) Surufatinib in Advanced Pancre-atic Neuroendocrine Tumours (SANET-p): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lan-cet Oncology, 21, 1489-1499.
https://doi.org/10.1016/S1470-2045(20)30493-9 |
| [61] | Capdevila, J., Fazio, N., Lopez Lopez, C., et al. (2019) Final results of the TALENT Trial (GETNE1509): A Prospective Multicohort Phase II Study of Lenvatinib in Patients (pts) with G1/G2 Advanced Pancreatic (panNETs) and Gastrointestinal (giNETs) Neuroendocrine Tumors (NETs). JCO, 37, 4106.
https://doi.org/10.1200/JCO.2019.37.15_suppl.4106 |
| [62] | Fazio, N., Kulke, M., Rosbrook, B., et al. (2021) Up-dated Efficacy and Safety Outcomes for Patients with Well- Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib. Targeted Oncology, 16, 27-35.
https://doi.org/10.1007/s11523-020-00784-0 |
| [63] | Lu, M., Zhang, P., Zhang, Y., et al. (2020) Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clinical Cancer Research, 26, 2337-2345.
https://doi.org/10.1158/1078-0432.CCR-19-4000 |
| [64] | Strosberg, J., Mizuno, N., Doi, T., et al. (2020) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results from the Phase II KEYNOTE-158 Study. Clinical Cancer Research, 26, 2124-2130.
https://doi.org/10.1158/1078-0432.CCR-19-3014 |
| [65] | Klein, O., Kee, D., Markman, B., et al. (2019) A Phase II Clinical Trial of Ipilimumab/Nivolumab Combination Immunotherapy in Patients with Rare Upper Gastrointestinal, Neu-roendocrine, and Gynecological Malignancies. JCO, 37, 2570. https://doi.org/10.1200/JCO.2019.37.15_suppl.2570 |
| [66] | Shen, L., Yu, X., Lu, M., et al. (2021) Surufatinib in Combination with Toripalimab in Patients with Advanced Neuroendocrine Carcinoma: Results from a Multicenter, Open-Label, Single-Arm, Phase II Trial. JCO, 39, e16199.
https://doi.org/10.1200/JCO.2021.39.15_suppl.e16199 |
| [67] | Ito, T., Masui, T., Komoto, I., et al. (2021) JNETS Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms: Diagnosis, Treatment, and Fol-low-Up: A Synopsis. Journal of Gastroenterology, 56, 1033-1044.
https://doi.org/10.1007/s00535-021-01827-7 |
| [68] | Strosberg, J.R., Caplin, M.E., Kunz, P.L., et al. (2021) Final Overall Survival in the Phase 3 NETTER-1 Study of Lutetium-177-DOTATATE in Patients with Midgut Neuroendo-crine Tumors. JCO, 39, 4112.
https://doi.org/10.1200/JCO.2021.39.15_suppl.4112 |
| [69] | Clement, D., Navalkissoor, S., Srirajaskanthan, R., et al. (2021) Efficacy and Safety of 177Lu-DOTATATE in Patients (pts) with Advanced Pancreatic Neuroendocrine Tumors (pNETs): Data from the NETTER-R International, Retrospective Registry. JCO, 39, 4116. https://doi.org/10.1200/JCO.2021.39.15_suppl.4116 |
| [70] | Nicolas, G.P., Ansquer, C., Lenzo, N.P., et al. (2020) 1160O An International Open-Label Study on Safety and Efficacy of 177Lu-Satoreotide Tetraxetan in Somatostatin Re-ceptor Positive Neuroendocrine Tumours (NETs): An Interim Analysis. Annals of Oncology, 31, S771. https://doi.org/10.1016/j.annonc.2020.08.1373 |
| [71] | Fross-Baron, K., Garske-Roman, U., Welin, S., et al. (2021) Lu-177-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants. Neuroendocrinology, 111, 330-343. https://doi.org/10.1159/000506746 |
